



A Pfizer Company

SAFETY DATA SHEET

Revision date: 20-Nov-2017

Version: 1.0

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Propofol Injectable Emulsion (Hospira, Inc.)

Trade Name: Propofol Injectable Emulsion

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

| Ingredient | CAS Number | EU EINECS/ELINCS List | GHS Classification | % |
|------------|------------|-----------------------------|--------------------|---|
|------------|------------|-----------------------------|--------------------|---|

SAFETY DATA SHEET

Material Name: Propofol Injectable Emulsion (Hospira, Inc.)
Revision date: 20-Nov-2017

Page 2 of 10
Version: 1.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

| | | | | |
|------------------|-----------|-----------|---|----|
| Benzyl Alcohol | 100-51-6 | 202-859-9 | Acute Tox.4 (H302) Acute Tox.4 (H332) | <1 |
| SODIUM HYDROXIDE | 1310-73-2 | 215-185-5 | Skin Corr. 1A (H314) | ** |
| Propofol | 2078-54-8 | 218-206-6 | Eye Irrit. 2A (H319) Skin Irrit. 2 (H315) STOT SE 3 (H335) STOT SE 3 (H336) Acute Tox. 4 (H302) | 1 |

| Ingredient | CAS Number | EU EINECS/ELINCS List | GHS Classification | % |
|---------------------|------------|-----------------------|--------------------|---|
| Lecithin | 8002-43-5 | 232-307-2 | Not Listed | * |
| Glycerol | 56-81-5 | 200-289-5 | Not Listed | * |
| Water for Injection | 7732-18-5 | 231-791-2 | Not Listed | * |
| Soybean oil | 8001-22-7 | 232-274-4 | Not Listed | * |
| Sodium benzoate | 532-32-1 | 208-534-8 | Not Listed | * |

Additional Information:

* Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions: None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

SAFETY DATA SHEET

Material Name: Propofol Injectable Emulsion (Hospira, Inc.)
Revision date: 20-Nov-2017

Page 3 of 10
Version: 1.0

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Benzyl Alcohol

| | |
|--------------------------|-----------------------|
| Bulgaria OEL - TWA | 5.0 mg/m ³ |
| Czech Republic OEL - TWA | 40 mg/m ³ |
| Finland OEL - TWA | 10 ppm |
| | 45 mg/m ³ |
| Latvia OEL - TWA | 5 mg/m ³ |
| Lithuania OEL - TWA | 5 mg/m ³ |
| Poland OEL - TWA | 240 mg/m ³ |

SODIUM HYDROXIDE

| | |
|--------------------------------|-----------------------|
| ACGIH Ceiling Threshold Limit: | 2 mg/m ³ |
| Australia PEAK | 2 mg/m ³ |
| Austria OEL - MAKs | 2 mg/m ³ |
| Bulgaria OEL - TWA | 2.0 mg/m ³ |
| Czech Republic OEL - TWA | 1 mg/m ³ |
| Estonia OEL - TWA | 1 mg/m ³ |

SAFETY DATA SHEET

Material Name: Propofol Injectable Emulsion (Hospira, Inc.)
 Revision date: 20-Nov-2017

Page 4 of 10
 Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

| | |
|---------------------------|-----------------------|
| France OEL - TWA | 2 mg/m ³ |
| Greece OEL - TWA | 2 mg/m ³ |
| Hungary OEL - TWA | 2 mg/m ³ |
| Japan - OELs - Ceilings | 2 mg/m ³ |
| Latvia OEL - TWA | 0.5 mg/m ³ |
| OSHA - Final PELs - TWAs: | 2 mg/m ³ |
| Poland OEL - TWA | 0.5 mg/m ³ |
| Slovakia OEL - TWA | 2 mg/m ³ |
| Slovenia OEL - TWA | 2 mg/m ³ |
| Sweden OEL - TWAs | 1 mg/m ³ |
| Switzerland OEL -TWAs | 2 mg/m ³ |

Propofol

| | |
|----------------------|----------------------|
| Pfizer OEL TWA-8 Hr: | 140µg/m ³ |
|----------------------|----------------------|

Glycerol

| | |
|---------------------------|-----------------------|
| Australia TWA | 10 mg/m ³ |
| Belgium OEL - TWA | 10 mg/m ³ |
| Czech Republic OEL - TWA | 10 mg/m ³ |
| Estonia OEL - TWA | 10 mg/m ³ |
| Finland OEL - TWA | 20 mg/m ³ |
| France OEL - TWA | 10 mg/m ³ |
| Germany (DFG) - MAK | 200 mg/m ³ |
| Greece OEL - TWA | 10 mg/m ³ |
| Ireland OEL - TWAs | 10 mg/m ³ |
| OSHA - Final PELs - TWAs: | 15 mg/m ³ |
| Poland OEL - TWA | 10 mg/m ³ |
| Portugal OEL - TWA | 10 mg/m ³ |
| Spain OEL - TWA | 10 mg/m ³ |
| Switzerland OEL -TWAs | 50 mg/m ³ |

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

SAFETY DATA SHEET

Material Name: Propofol Injectable Emulsion (Hospira, Inc.)
Revision date: 20-Nov-2017

Page 5 of 10
Version: 1.0

9. PHYSICAL AND CHEMICAL PROPERTIES

| | | | |
|---------------------------|---------------|--------------------------|--------------------|
| Physical State: | Oily emulsion | Color: | White |
| Odor: | None | Odor Threshold: | No data available. |
| Molecular Formula: | Mixture | Molecular Weight: | Mixture |

| | |
|-------------------------------------|--------------------|
| Solvent Solubility: | No data available |
| Water Solubility: | Soluble |
| pH: | 7-8.5 |
| Melting/Freezing Point (°C): | No data available |
| Boiling Point (°C): | No data available. |

Partition Coefficient: (Method, pH, Endpoint, Value)

Propofol

Measured Log P 3.8

Water for Injection

No data available

Soybean oil

No data available

Glycerol

No data available

Benzyl Alcohol

No data available

Sodium benzoate

No data available

SODIUM HYDROXIDE

No data available

Lecithin

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: 0.955

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

SAFETY DATA SHEET

Material Name: Propofol Injectable Emulsion (Hospira, Inc.)
Revision date: 20-Nov-2017

Page 6 of 10
Version: 1.0

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The following information is available for the individual ingredients.

Short Term:

May cause eye and skin irritation (based on components) .

Known Clinical Effects:

Clinical use of this drug has caused slow heart rate (bradycardia), decrease in blood pressure (hypotension), respiratory depression, skin rash, cough, drowsiness, sleepiness, dizziness, sedation, and gastrointestinal disturbance.

Acute Toxicity: (Species, Route, End Point, Dose)

Propofol

Rat Oral LD 50 500 mg/kg
Mouse Oral LD 50 1100 mg/kg
Rabbit Dermal LD 50 > 2000 mg/kg

Glycerol

Rat Oral LD 50 12600 mg/kg

Benzyl Alcohol

Rat Oral LD50 1230 mg/kg
Rat Para-periosteal LD50 53mg/kg
Rat Inhalation LC50 >4.178mg/L

Sodium benzoate

Rat Oral LD50 4,070 mg/kg
Mouse Oral LD50 1600mg/kg

Lecithin

Rat Oral LD50 > 8 ml/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Propofol

Eye Irritation Rabbit Irritant
Skin Irritation Rabbit Irritant
Skin Irritation Rat Severe Irritant

Glycerol

Skin Irritation Rabbit Mild
Eye Irritation Rabbit Mild

Benzyl Alcohol

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Minimal
Skin Irritation Guinea Pig Moderate

SAFETY DATA SHEET

Material Name: Propofol Injectable Emulsion (Hospira, Inc.)
Revision date: 20-Nov-2017

Page 7 of 10
Version: 1.0

11. TOXICOLOGICAL INFORMATION

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Glycerol

28 Day(s) Rat Oral 16800 mg/kg LOEL Endocrine system

Sodium benzoate

10 Day(s) Rat Oral 27370 mg/kg LOEL Liver, Blood

10 Day(s) Mouse Oral 45 g/kg LOEL Liver, Kidney, Blood, Ureter, Bladder

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Propofol

Reproductive & Fertility Rabbit Intravenous 15 mg/kg/day No effects at maximum dose

Reproductive & Fertility Rat Intravenous 15 mg/kg/day No effects at maximum dose

Glycerol

Reproductive & Fertility-Males Rat Oral 100 mg/kg LOEL Fertility

Sodium benzoate

Embryo / Fetal Development Rat Oral 44 g/kg LOEL Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Propofol

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Mitotic Gene Conversion *Saccharomyces cerevisiae* Negative

In Vitro Cytogenetics Chinese Hamster Ovary (CHO) cells Negative

In Vitro Chromosome Aberration Human Lymphocytes Negative

In Vivo Micronucleus Mouse Negative

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Benzyl Alcohol

Pimephales promelas (Fathead Minnow) EPA LC50 96 Hours 460 mg/L

Daphnia magna (Water Flea) OECD EC50 48 Hours 230 mg/L

Pseudokirchneriella subcapitata (Green Alga) OECD EC50 72 Hours 500 mg/L

Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

Benzyl Alcohol

Daphnia magna (Water Flea) OECD 21 Day(s) EC50 66 mg/L Reproduction

SAFETY DATA SHEET

Material Name: Propofol Injectable Emulsion (Hospira, Inc.)
Revision date: 20-Nov-2017

Page 8 of 10
Version: 1.0

Persistence and Degradability:

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Benzyl Alcohol

OECD Activated sludge Ready 92% After 14 Day(s) Ready

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Propofol

Measured Log P 3.8

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Benzyl Alcohol

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 202-859-9 |

SODIUM HYDROXIDE

| | |
|------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
|------------------------------------|------------|

SAFETY DATA SHEET

Material Name: Propofol Injectable Emulsion (Hospira, Inc.)
 Revision date: 20-Nov-2017

Page 9 of 10
 Version: 1.0

15. REGULATORY INFORMATION

| | |
|--|------------|
| CERCLA/SARA Hazardous Substances and their Reportable Quantities: | 1000 lb |
| California Proposition 65 | 454 kg |
| Inventory - United States TSCA - Sect. 8(b) | Not Listed |
| Australia (AICS): | Present |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Present |
| EU EINECS/ELINCS List | Schedule 5 |
| | Schedule 6 |
| | 215-185-5 |

Propofol

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Schedule 4 |
| EU EINECS/ELINCS List | 218-206-6 |

Lecithin

| | |
|--|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| REACH - Annex IV - Exemptions from the obligations of Register: | Present |
| EU EINECS/ELINCS List | 232-307-2 |

Glycerol

| | |
|---|--|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| REACH - Annex V - Exemptions from the obligations of Register: | Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bio accumulative, and toxic or very persistent and very bio accumulative in accordance with the criteria set out in Annex XIII, except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an equivalent level of concern |
| EU EINECS/ELINCS List | 200-289-5 |

Water for Injection

| | |
|--|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| REACH - Annex IV - Exemptions from the obligations of Register: | Present |
| EU EINECS/ELINCS List | 231-791-2 |

Soybean oil

SAFETY DATA SHEET

Material Name: Propofol Injectable Emulsion (Hospira, Inc.)
Revision date: 20-Nov-2017

Page 10 of 10
Version: 1.0

15. REGULATORY INFORMATION

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 232-274-4 |

Sodium benzoate

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 208-534-8 |

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage
Skin corrosion/irritation-Cat.2; H315 - Causes skin irritation
Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation
Specific target organ toxicity, single exposure; Narcotic effects-Cat.3; H336 - May cause drowsiness and dizziness

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Revision date: 20-Nov-2017
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet